Last updated on August 2018

Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis

Brief description of study

To demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with non-radiographic axial spondyloarthritis at Week 16 as well as week 52 and long term efficacy and safety up to Week 104.

Clinical Study Identifier: NCT02696031

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Germering, Germany